lecular imaging technologies in patient diagnosis and followup has the potential to enhance care. To discuss developments and issues required to improve diagnostics and management of NET patients, with specific focus on the latest advances in molecular imaging and biomarker science, 17 global leaders in the fields of NET, molecular imaging and biomarker technology gathered to participate in a 2-day meeting hosted by Prof. Kjell Öberg at the University of Uppsala in Sweden. During this time, findings were presented regarding methods with potential prognostic and treatment applications in NET or other types of cancers. This paper describes the symposium presentations and resulting discussions. 
Introduction
Neuroendocrine tumors (NET) are malignant solid tumors that arise in hormone-secreting tissues of the diffuse neuroendocrine system. During the early stages of disease, NET are generally slow growing and nonsymptomatic, but they have the potential to secrete excessive quantities of bioactive amines. Late in the disease course, typically following tumor metastasis to the liver, hormonal hypersecretion can lead to well-defined and debilitating clinical syndromes, such as flushing and diarrhea of carcinoid syndrome, and a variety of hormone-dependent syndromes from functioning pancreatic NET (pNET). Although several guidelines have been agreed upon to standardize diagnostics, diagnosis is typically only made after tumors produce clinical symptoms and are metastatic due to the insidious natural history of NET [1, 2] .
Although traditionally understood as a rare disease, the incidence and prevalence of NET has increased greatly in the past 3 decades, and NET are now a more common form of gastrointestinal neoplasm than both gastric and esophageal cancers combined [3] . A dramatic improvement in survival time was observed among patients with metastatic NET diagnosed between 1988 and 2004, coincident with the introduction of the somatostatin analogue octreotide in 1987 for the control of carcinoid syndrome, a major cause of morbidity and mortality if untreated [3] . Although octreotide has had a substantial effect on relieving symptoms of functioning NET [4] and has shown antiproliferative effects in patients with welldifferentiated metastatic NET of the small intestine [5] , therapeutic interventions are usually noncurative once metastasis has occurred. Cytotoxic therapies have demonstrated some effect in controlling pNET growth and spread [6] . New targeted therapies such as mTOR (mammalian target of rapamycin) or tyrosine kinase inhibitors [7, 8] have demonstrated antitumor efficacy in pNET [8, 9] . An unmet need exists for additional therapies and especially for earlier disease detection and diagnosis.
Although advances in the past few years have been encouraging, progress in the diagnosis and outcome of NET has generally occurred at a modest rate. Many different variables may contribute to this situation, including the peculiarities of NET themselves. For example, the relative rarity and heterogeneity of the disease, the multiplicity of NET classification systems, and the historical lack of welldesigned clinical trials have all impeded progress in this field. Additionally, as NET are a diverse set of tumors that can exhibit variable behavior, histological differentiation and clinical course, individualized therapy is required that cannot be easily generalized to larger populations. It has previously been identified that in order to improve outcome in NET, a better understanding of NET biology combined with more reliable serum markers and better techniques to identify tumor localization and small lesions are needed [6, 9] . In general, there is a delay of 3-4 years before the correct diagnosis is made by the treating physician.
The publication of well-designed clinical trials in patients with NET during the last few years, including the PROMID study, which established the antitumor effect of octreotide LAR 30 mg/month in patients with functioning or nonfunctioning metastatic NET of the midgut (small intestine) [5] , the RADIANT series of trials evaluating the mTOR inhibitor everolimus alone or in combination with octreotide LAR [7, 10, 11] , late-stage trials of sunitinib for patients with metastatic well-differentiated pNETs [8] and evaluation of bevacizumab (in combination or alone) in patients with NETs or neuroendocrine carcinomas [12, 13] , will undoubtedly provide new insights into patient care and perhaps serve to hasten the pace of further biomarker development [12] . Identified markers for therapeutic response, such as the presence of sst (somatostatin subtype receptors) [14] , the absence of O 6 -methylguanine DNA methyltransferase with temozolomide [15] and loss of heterozygosity on chromosome 18 [16] , or the expression of PTEN or TC1 protein in pNET [17] , may enable more personalized and targeted therapy [18] .
Novel Biomarker Applications in NET
Biomarkers are physical, functional or biochemical indicators of disease that can provide vital information for assessing disease development and prognosis, predicting response to therapy and estimating the likelihood of adverse events associated with therapy [19] . For many diseases, the desire to achieve early diagnosis and curative treatment has led to the current drive to identify new clinically relevant biomarkers with prognostic and/or predictive value.
Status of NET Biomarkers and Unmet Need
Sensitive and specific biomarkers are still largely lacking, and current assays fail to identify biomarkers at an early stage in disease progression in most conditions, including the rare malignancy NET. Although some NET biomarkers do exist ( table 1 ) , sensitive and specific markers that predict tumor growth and behavior are generally scarce [6] . NET differ from other types of neoplasias as they synthesize, store and secrete characteristic peptides, providing an opportunity for their use as biomarkers in diagnosis. One of these peptides is chromogranin A (CgA), the plasma levels of which are elevated in approximately 80-90% of patients with NET of the gut, and CgA levels also correlate with tumor burden and recurrence [20] . Although CgA is the best available biomarker and accessible via minimally invasive blood sampling, CgA only serves as a general NET marker and cannot distinguish among different forms of NET. Furthermore, CgA testing is usually performed when symptoms present, which is often associated with cancer metastasis. Although CgA monitoring provides information that is helpful in delineating tumor burden, rate of growth and subsequent treatment therapies, additional more sensitive tumor-specific biomarkers are required. Similarly, the urinary 5-hydroxyindoleacetic acid test is generally performed too late in the disease course, i.e. when liver metastases occur, and it does not warrant serious consideration as a diagnostic screening test [21] .
Genetic Analysis
Recent data from exome sequencing in pNET have shown significant mutations in DAXX/ATRX and MEN1, which has to be translated into clinical practice [17] .
Using biomathematical tools, genes with potential diagnostic or therapeutic relevance might be identified via mRNA measurements. For example, NET of different tumor grades present a different set of transcripts, which provides information regarding tumor status and prognostic capacity. Analysis with quantitative real-time PCR has identified five genetic markers that separate genetic appendiceal carcinoids into benign or malignant and mixed cell forms. A mitosis-regulatory gene NAP1L1 , an adhesin MAGE-D2 , an estrogen antagonist and metastasis marker MTA1 , the apoptotic marker NALP and CgA were identified from 42 appendiceal samples [22] . Using tools such as perceptron classification and principal component analysis, it is hoped that models could be used to discriminate tumors, predict how tumors might behave and estimate the probability of metastasis [22, 23] .
Supervised machine learning can be used to classify small-intestine NET subtypes and accurately predict metastasis on the basis of gene expression measurements [23] . The advent of machine learning within the context of gene expression relies on designing algorithms that delineate gene expression patterns within tumor cells. The effectiveness of such mathematical tools relies on the selection of appropriate housekeeping genes. A predictive gene-based model constructed for small-intestinal NET identified a panel of molecular markers related to tumorigenicity, metastasis and hormone production. Other than those previously identified in appendiceal carcinoids, identified markers included: Ki-67, a protein associated with cell proliferation; Survivin , an inhibitor of apoptosis [24] ; FZD7 , known to be highly expressed in well-differentiated colorectal cancer tumor cells; Kiss1 , a metastasis-suppressing gene, and NRP2, a protein that interacts with vascular endothelial growth factor [23] . Furthermore, gene expression profiling and supervised machine learning could be used to classify NET subtypes and accurately predict metastasis.
A majority of small-intestinal NETs (carcinoids) show losses on chromosome 18. However, no genotype-phenotype correlation has been found. Sometime losses of the whole chromosome 18 occur [23] . While the molecular pathologies that lead to tumorigenesis and metastatic processes are relatively unknown in NET, elucidating these molecular triggers will provide targets for pharmacological intervention. A recent study by Leja et al. [25] , using Affymetrix microarrays and advanced bioinformatic analysis to recognize differentially and specifically expressed genes, identified six novel marker genes for neuroendocrine small intestinal tumors (carcinoids): paraneoplastic antigen Ma2 (PNMA2) , testican-1 precursor (SPOCK1) , serpin A10 (SERPINA10) , glutamate receptor ionotropic AMPA 2 (GRIA2) , G-protein-coupled receptor 112 (GPCR112) and olfactory receptor family 51 subfamily E member 1 (OR51E1) . All markers were expressed in both NET and normal neuroendocrine cells except for GRIA2 , which was specifically expressed in NET cells. The authors suggested that GPCR112 and OR51E1 may be potential targets for antibody-based diagnosis and therapy as these genes encode proteins associated with the plasma membrane [26] . To date, studies using gene expression have led to the inference of potential uses of established and novel gastrointestinal NET markers ( table 2 ) [27] .
Novel Methods for Genetic Analysis
Cancer companion diagnostics is a pathway-oriented approach to cancer analysis that integrates mutational analyses with protein activity biomarkers in clinical samples from patients treated with molecularly directed drugs. The goal is to develop diagnostics that better predict patient response to a drug and to create improved methods for monitoring therapy. A mutational analysis will be conducted in all genes involved in the pathway [28] . The padlock probe technique enables detection of single nucleotide variants and other tumor-or cell-specific transcriptomic markers in tissue specimens in situ at the single-cell level. The assay could be of great value for clinical pathology [29] . The selector probes, by contrast, are used to direct the circularization of genomic DNA sequences, targeted for sequence analysis by next-generation sequencing techniques [30, 31] . The selector technique allows for highly specific and cost-effective amplification of sets of 20-500 genes, focusing the sequencing power of the next-generation sequencing instruments to part of the genome that is most relevant for diagnostics, affording deeper sequencing of genetically heterogeneous tumor tissues.
Blood-Based Analysis

PNMA2 Autoantibodies
Building on results derived from genetic analysis, PNMA2 has been evaluated as a potential biomarker. Specifically, the analyses have centered on the prognostic significance of PNMA2 autoantibodies in blood. A novel indirect ELISA was set up to detect PNMA2 autoantibodies in serum and plasma samples from 124 patients with NET of the small intestine at different stages of disease. Among patients with a primary tumor (n = 36), lymph node metastasis (n = 38) and liver metastasis (n = 50), the novel PNMA2 autoantibody ELISA showed high sensitivity, specificity and accuracy, with receiver-operating characteristics curve analysis demonstrating an area of 0.734 for liver metastasis, 0.802 for lymph node metastasis and 0.816 for a primary NET of the small intestine [32] . As such, the assay was able to stratify between patients with a primary NET and healthy controls (area under the curve >0.730). Patients with an NET of the small intestine who expressed low levels of Ma2 autoantibodies exhibited significantly longer progression-and recurrence-free survival ( fig. 1 ) [32] .
This analysis was further expanded to patient samples with typical and atypical lung carcinoids to determine if this prognostic screen could be used in the diagnosis of other NET. Higher levels of Ma2 autoantibodies were Progression-and recurrence-free survival of patients with primary small-intestine NET after surgery with curative intent depend on Ma2 autoantibody titer [32] . measured in samples of patients with typical and atypical lung carcinoids compared with control samples. This study illustrates an early potential translational success as Ma2 autoantibodies may be novel, sensitive biomarkers for small-intestine NET that may allow for early detection of uncontrolled cellular proliferation prior to tumor metastasis with the concomitant possibility of curative therapy.
Identification of Circulating Tumor Cells Circulating tumor cells (CTC) are cells that have been dislodged from the tumor mass and circulate in the body through the blood. The fact that CTC can be found in patients before primary tumors are detected point to their potential role in early diagnosis and prognostication. The presence of tumor cells in blood also provides ready, minimally invasive access to tumor tissue for molecular analyses, e.g. for monitoring responses to therapy. CTC are currently used as an independent prognostic marker in metastatic breast cancer, with high CTC levels during therapy associated with a poor outcome [33] . As it is unknown if NET release CTC and/or if potential CTC from NET express epithelial cell adhesion molecule (EpCAM), an antigen commonly expressed on carcinomas, the first systematic analysis of EpCAM expression in NET was performed using CellSearch, the only FDA-approved method to detect CTC in whole blood [34] .
In this study, EpCAM protein expression was evaluated in 74 samples of formalin-fixed, paraffin-embedded NET tissue by immunohistochemistry [34] . Seventynine patients with metastatic NET, 42 midgut, 5 unknown primary, 19 pancreatic and 13 bronchopulmonary tumors, had blood samples drawn for CTC isolation and enumeration, utilizing the CellSearch platform. Patients were classified as having progressive or nonprogressive disease on the basis of serial imaging. Strong homogeneous membranous EpCAM expression was observed in all ileal NET (n = 26) and pNET (n = 16), whereas variable EpCAM expression was observed in bronchopulmonary NET (n = 13). Forty-three percent of midgut and 21% of pNET had CTC detected, with a range of 0-62 and 0-11, respectively. The absence of CTC was strongly associated with stable disease (p < 0.001). There were moderate correlations between CTC levels and urinary 5-hydroxindoleacetic acid (p = 0.007), and between CTC levels and burden of liver metastases (p < 0.001). There was no or only a low correlation between CTC levels and Ki-67 (p = 0.59) and serum CgA (p = 0.03; fig. 2 ) [34] .
Protein Analysis Human Protein Atlas Initiative
The Swedish Human Protein Atlas (HPA) project has been set up for the systematic generation of specific antibodies on a global scale and to utilize these antibodies for studies of the corresponding proteins [35] . This effort relies on an antibody-based proteomics strategy [36] applied to combine high-throughput generation of affinitypurified polyclonal antibodies with (i) immunohistochemistry-based protein profiling on tissue microarrays containing human normal and cancer tissues, and (ii) immunofluorescence-based protein profiling of the subcellular proteome. The ultimate goal of the HPA is threefold: (i) to generate and validate antibodies against all human proteins (a major isoform for each protein-encoding gene); (ii) to create an information database including a map of protein expression patterns in cells and human tissues, and (iii) to utilize affinity reagents and protein expression data to identify and explore biomarkers of clinical relevance. This large-scale project hopes to provide new diagnostic, prognostic and treatment-predictive markers not only for NET but also for many other diseases. Antibody-based proteomics appears as an advantageous route to further develop diagnostics and find new therapeutic approaches in oncology [37] , as this strategy allows numerous functional assays to be performed on sample tissue, ranging from a simple ELISA to detailed localization studies using fluorescent probes and immunoprecipitation pull-down assays. Protein expression patterns in normal human tissue from 144 individuals and cancer tissue, corresponding to the 20 most common forms of human cancer, from 216 patients were determined for over 15,500 antibodies, corresponding to over 12,200 unique genes (approximately 60% of all human protein-coding genes). Moreover, all antibodies were tested on over 40 cell lines. All data including underlying images are freely available at the HPA web portal (www.proteinatlas.org) [38] [39] [40] . The HPA can also be used as a tool for pathology with opportunities to identify different types of biomarkers with in silico-based methods [41] . The HPA can also be utilized for finding clinically useful biomarkers for other diseases than cancer, exemplified by the recent identification of novel surface markers expressed on β-cells in Langerhans islets of the pancreas, which could be used to develop tools for positron emission tomography (PET) [42] . As various endocrine cells are represented in normal tissue and 4 different endocrine tumors are also used for protein profiling, it is hoped that similar insights based on the HPA could be identified in NET. An overview of the HPA process is provided in figure 3 .
Novel Methods for Sensitive and Specific Protein Detection Improvements in sensitivity and throughput of protein detection methods will be needed to identify novel biomarkers to observe complex protein modifications and interactions. The proximity ligation assay (PLA) is an immunoassay for protein analysis for the measurement and characterization of proteins with high specificity and sensitivity via DNA ligation and amplification reactions. The method relies on converting detection reactions to DNA reporter sequences. PLA probes with attached oligonucleotides are designed to bind pair-wise to target proteins to form amplifiable tag sequences. Upon proximal binding of a pair of probes to the target molecule, the DNA strands are brought into close proximity and allowed to hybridize to a connector oligonucleotide. The DNA strands can then be joined by enzymatic ligation to form a reporter DNA molecule. Subsequent amplification of the DNA molecule generates a signal that can be amplified using PCR, allowing for the detection of minute amounts of protein in serum ( fig. 4 ) . The technique allows the specificity of detection to be enhanced by requiring simultaneous target detection via three or more antibodies [43] . Importantly, this enhanced specificity can be obtained without problems of cross reactivity when more 23 proteins are targeted in the same reaction, allowing multiplexed protein detection [44] . The sensitivity of the PLA technique for plasma protein measurement renders the technique suitable for detection and identification of rare protein molecules in blood, potentially allowing for new classes of promising biomarkers to be identified from biobanked samples. The attraction of serum or plasma biomarkers lies in their potential to reveal disease processes throughout the body and guide selection of therapy and follow-up using minimally invasive blood sampling. The PLA method can also be combined with standard fluorescent microscopy for the detection of proteins or protein-protein interactions and posttranslational protein modifications as activation markers in tissue sections using in situ PLA [45] . A major application of in situ PLA is to demonstrate the dynamic interplay between signaling molecules [46] . The technique provides an insight into protein complex association during cellular transformation events and cellular signal transmission.
Aptamers and Other Affinity Regents Although monoclonal antibodies have provided a rich source of ligands for detecting the location and activity of target proteins, the number of new targets outstrips the capacity of the methodology for generating and screening cancer biomarkers. Alternative approaches to new ligand discovery include ('aptamers') acid that can be used to target a range of molecules via specific affinity reactions [47, 48] . The term aptamers is derived from the Latin term aptus meaning 'to fit'. Aptamers are usually 15-60 nucleotides in length that form intramolecular interactions in solution, allowing the formation of tight interaction with the surface of target molecules. Because of the extraordinary diversity of shapes that aptamers can form these agents can be developed to bind to a vast array of molecular targets. The specificity is such that closely related proteins can be distinguished, including nonidentical members of a protein family, and even between different conformation states of the same protein. In addition to their remarkable specificity, aptamers typically bind to targets with high affinity and are developed entirely in the test tube (an advantage compared with monoclonal antibodies). Typical binders have molecular weights of around 5,000 kDa, can be readily modified by chemical methods to incorporate radionuclides, fluorophores and other functional groups site specifically and stoichiometrically, and can be immobilized on various surfaces, beads and nanoparticles without loss of binding performance. This technology offers unique possibilities in drug development, for example in target validation and in the evaluation of binding properties of early-stage leads as well as in the identification and quantification of biomarkers [48] [49] [50] .
Mass Spectrometry Analysis Detection and characterization of protein biomarkers in any tissue or body fluid, e.g. human CSF, can be performed using modern mass spectrometry (MS) methods, such as MALDI TOF MS (matrix-assisted laser desorption ionization tandem time-of-flight MS), and high-resolution nanoelectrospray MS, such as ESI-FTICR (Fourier Transform Ion Cyclotron Resonance) MS or Orbitrap MS, in conjunction with multidimensional capillary electrophoresis, capillary electrochromatography, nanoor microliquid chromatography and microchip-based devices for preclinical as well as clinical studies ( fig. 5 ) [51] [52] [53] .
MS analysis has the potential to identify and distinguish between modified proteins within the tissue extract or body fluid (e.g. CSF) and can be used for the discovery of valid biomarkers, complementing other diagnostic methods such as immunoassay and therapeutic imaging technologies.
It is also possible that miniaturized mass spectrometers (possibly hand-held devices) may soon be available at the point of care, although appropriate sample introduction systems are needed for optimal performance [52] . Fig. 4 . Schematic of the solid-phase PLA method [43] . A = Samples are incubated with antibodies preimmoblized on microparticles; B = microparticles are washed and incubated with pairs of PLA probes; C = oligonucleotides on PLA probes are ligated upon proximal binding of a common antigen and addition of a connector oligonucleotide. This is followed by amplification and detection of the ligated products by quantitative real-time PCR, the primers of which are indicated by arrows. 
Novel Imaging Applications in NET
Molecular imaging technologies have undergone an explosion in growth over the past few decades and now play a central role in clinical oncology. The primary role of imaging in cancer diagnosis has traditionally been in diagnosis and staging, to precisely locate the primary tumor and metastatic lesions. However, new imaging techniques provide biomarkers of specific molecules (e.g. protein kinases) and cellular processes (perfusion, hypoxia, apoptosis, cell death, proliferation and metastasis) that influence tumor behavior and response to therapy. This functional information can lead to a greater understanding of how cancer arise, how tumors progress and metastasize, and as a guide to therapy. Importantly, functional or molecular imaging measurements with PET, singlephoton emission computed tomography (SPECT) or magnetic resonance imaging (MRI) often provide pharmacodynamic biomarkers which can assist in identifying which therapies benefit which patients.
PET and SPECT Biomarkers
Rapid developments in synthetic chemistry have provided new potential tracers for molecular imaging in oncology. The function of specific metabolic pathways or expression levels of receptors and enzymes can now be measured selectively using an array of various tracers with different properties. These imaging techniques can now be used to measure metabolic changes within the tumor during and after treatment.
To date, there are a number of tracer molecules for use in PET, which have reached a level of clinical use, although some require further validation. The four preferred positron-emitting radioisotopes are fluorine-18, carbon-11, nitrogen-13 and oxygen-15. The reason why these are most common center on the ease in which they can be substituted into biomolecules without affecting function. The relatively short half-life of 11 C, which was previously considered to be a disadvantage, has rekindled the interest in 11 C tracer molecules as the short half-life permits repeat imaging, providing real-time data on a number of cellular processes. Repetitive studies can be performed using tracers limited by short half-lives (2-20 min) and to collect data for 'time dimension' analyses [53] [54] [55] .
A variety of PET and SPECT imaging biomarkers is currently applicable to NET. The majority of all NET express the sst 2 protein, which can be tightly bound by radioactively labeled octreotide (somatostatin receptor scintigraphy) and this is now routinely used [56] in the diagnosis and staging of NET. Other functional imaging techniques used in NET include metaiodobenzylguanidine scintigraphy, PET using F-DOPA-based tracers revealed 18 F-DOPA PET/computed tomography (CT) is the optimal imaging modality for staging in carcinoid patients and 11 C-5-HTP PET/CT for islet cell tumor patients [59] . A drawback of using 11 C-5-HTP is that the high concentrations of radioactivity in the urine can produce image reconstruction artifacts that reduce quality, although carbidopa pretreatment improves the detection capacity of 11 C-5-HTP PET [61] . Another problem is the poor availability of the technique; only two centers in the world (Uppsala, Sweden, and Groningen, The Netherlands) can produce 11 C-5-HTP. Future developmental aims are to coordinate gene transcript analysis with imaging techniques such as PET to allow for a more accurate and early diagnosis of specific indicators of NET. PET/CT with 68 Ga-DOTA-GOC or DOTATATE is likely to replace somatostatin receptor scintigraphy in the future as it offers better resolution [57, 62] and provides a quantitative method for peptide receptor radionuclide therapy [63] as well as being less expensive than the other PET tracers ( fig. 7 ) . PET/CT triphasic imaging using 68 Ga DOTA-GOC for the therapeutic management of patients with NET improves anatomical localization ( fig. 8 ). These methods are similarly sensitive, deliver complementary information and contribute equally to therapeutic decision-making [64] . FDG-PET is useful in patients with poorly differentiated tumors. New PET tracers marking apoptosis and proliferation require further study [65] . 
WB-PET-MRI
Whereas in the past imaging was focused on specific organs, today disease-specific WB, multimodality imaging is possible and is especially attractive in the case of systemic disease [65, 66] . Multimodality WB approaches revealing functional information from PET as well as anatomical information from CT or MRI are particularly appealing. Although PET/CT has been described as the imaging modality of choice for working up most common tumor entities as well as some of the rare malignancies [67] , a major drawback of CT is that soft tissue is imaged with little contrast and significant radiation is applied to the patient. Additionally, PET and CT scans cannot occur simultaneously. They potentially may cre- ate image artifacts that could hinder interpretation of the two overlaid scans. Thus, researchers have attempted to develop a single machine incorporating both applications. Additionally, since MRI can also be used to obtain anatomical images, other researchers have envisaged the PET-MRI combination. The goal is to include simultaneous data acquisition from both modalities, resulting in combined functional and morphological images with an excellent soft-tissue contrast, good spatial resolution of the anatomy, accurate temporal and spatial image fusion and lower costs [68] . A potential PET-MRI may have application in tumor identification, staging and grading, therapy evaluation and tumor surveillance, thus improving patient management [69] .
A potential treatment monitoring application of this method is also possible as, following tumor necrosis or apoptosis, tumor signals decrease commensurate with the increased mobility of water molecules. A second technique uses apparent diffusion coefficient (ADC). ADC is a measure of the diffusion path length for a water proton over the timescale of a few tens of milliseconds: since viable cells impose barriers to diffusion, the ADC may be a proxy for the amount of nonviable or dead material in the tumor, with a low ADC corresponding to a highly proliferative mass of packed cells. ADC is relatively easy to measure, and since it is an intrinsic biophysical property of the water protons rather than an MR parameter, it should be fairly robust. In a recent study by Liapi et al. [70] , patients with hepatic metastasis from a primary NET were treated with transcatheter arterial chemoembolization. Treatment response was evaluated by contrast-enhanced and diffusion-weighted MRI. Following therapy, mean tumor size and percentage enhancement in the arterial and portal venous phases decreased significantly (p < 0.0001). The authors concluded that contrastenhanced and diffusion-weighted imaging showed significant changes (1.51 vs. 1.79 × 10 -3 mm 2 /s, p < 0.0001) after transcatheter arterial chemoembolization in NET and that ADC can be used to assess response of targeted tumors [70] . Ongoing projects in the US and Europe are aiming at qualifying ADC as a biomarker in drug trials. In addition, WB-MRI may have a role in tumor surveillance when repeated evaluations are required.
Several 'biomarkers' are used in MRI evaluation, the most familiar of which are vascular measurements. Such an example is the transfer constant for a gadolinium chelate contrast agent into the tumor, k trans , derived from dynamic contrast-enhanced MRI [71, 72] . This MRI method is currently still under investigation as a prognostic technique. Emerging MR biomarkers measure oxygen delivery and consumption in tumors, such as deoxyhemoglobin concentrations in the tumor measured by the MRI R 2 and R 2 * relaxation rates, while another group of biomarkers uses the effect of changes in the concentration of dissolved paramagnetic dioxygen molecules on the water protons measured through the R 1 relaxation rate, a proxy for changes in the free oxygen tension in tumor voxels. 1 H-MR spectroscopy (MRS) provides biomarkers of proliferation through choline metabolites as measures of the choline pathway, while 13 C-MRS can provide measurements of abundant metabolites giving insights into tumor metabolism. These approaches have been limited by the very poor sensitivity of MRS. However, emerging techniques of hyperpolarized MRS are likely to lead to a resurgence of interest in this topic, although hyperpolarized MRS has not been evaluated clinically. Finally, MRS can provide measurements of drug concentrations and metabolism, particularly where the drug contains fluorine. In contrast to PET, MRS is very insensitive, and only practical for drugs of very low potency that approach millimolar concentrations in the tissue. Regarding patients with NET, currently available techniques can be used for the evaluation of liver metastases from NET primaries, but methods may require further development before application to lung metastases or primary NET [73] .
Expert Opinion and Conclusions
Challenges for practitioners of NET include detection of disease before metastasis, detection of tumor remnants after surgery, reliable monitoring of therapeutic efficacy and translating findings into clinical practice. Assays at the point of care, early diagnosis and personalized therapy are all healthcare goals. It is hoped that integrating the latest techniques in capturing, enriching and visualizing cancer cells in the evaluation of NET can improve patient outcome in the clinic.
In general, the lack of a clear therapeutic target in patients with NET is a point of frustration for researchers. However, the fact that most hormonally related symptoms from functioning NET can be controlled by somatostatin analogues, particularly octreotide, is very encouraging, and it was suggested that this success may contribute a slightly more optimistic tune as further difficult research is undertaken. The view that NET are a sort of 'Rosetta stone' was also articulated, whereby the study of proliferative and secretory pathways in NET could provide insight into deciphering the mechanism for tumor growth in other cell types. The following outlines a few 
